Project Grant R61CA291201
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$235K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $424,734 to the University of Illinois to develop a novel spatial proteomics approach that integrates 3D microscopy techniques with bottom-up proteomic assays. The goal is to create deep proteome profiles of specific immune cells located in different subregions of a tumor. The project aims to 1) develop a workflow for 3D photobleaching-mediated spatial fluorescence encoding of immune...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award of $405,497.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a compact viral system for robust, concurrent CRISPR activation and interference (CRISPRa/i) in primary murine immune cells. The goal is to use this system to map the gene regulatory network controlling BCL11B activation and T cell lineage commitment. Key innovations include CRISPR RNA-scaffolds to recruit...
This federal Project Grant award of $142,065 from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports the development of computational frameworks to model the impact of external signals on a cell's internal transcription factor activity. The key products and services to be delivered under this award include: Computational methods to more accurately deconvolve cell type fractions and gene expression from bulk RNA-seq and spatial transcriptomics data. A...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This Project Grant award, valued at $574,808, was provided by the National Science Foundation (NSF) through its Engineering program (CFDA 47.041) to Duke University. The project aims to investigate the origins of cellular heterogeneity in T cells, which are critical for immune system function and have applications in cancer therapies like CAR T-cell therapy. The research will leverage advanced technologies, including spatial proteomic multiplexed imaging, in vitro cell tracking, and engineered...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
This $1,449,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to study the fundamental regulation of extrachromosomal DNA (ecDNA) in cancer genomes. The project aims to develop new live-cell chromatin labeling strategies and integrate advanced imaging, synthetic genome engineering, and optical/genetic perturbation to systematically investigate how ecDNA orchestrates massive...